BeiGene, Ltd.
06160
2021 12 31
2021 12 31
13.09
571 XIVA
2021 12 31
2021 12 31
2021 12 31
2021 12 31
2022
1 2022 2 25
2022 3 31 2021 12 31
1
1995 (Private Securities Litigation
Reform Act of 1995)
10-Q
2022 2 25
Anthony C. Hooper Margaret
Han Dugan Donald W. Glazer Michael Goller Ranjeev Krishana
Thomas Malley Alessandro Riva Corazon (Corsee) D. Sanders
2
1
2021
2021 1.968
1.001 96.6%
6.340 3.089 105.3%
2022 2 25 BGNE
06160 688235
2021
(John V. Oyler)
2021
45
16 6
5
(CLL)
TIGIT (ociperlimab)
2021 40
2022 TIGIT 3
3
2021
2021 12 31 66.2
2021 9 30 39.2 2020 12
31 46.6 2021 12 31 2022 1
3
2021 27
5.078 1.15 34
2021 12 15
2021 20 13
2.629 36
2021 12 15
2021 2.14 12
1.001 3.089
2021 1.968 6.340
1.001 3.089
2021 8,760
2.180 1,830 4,170
2020
2020 6
2021 5,440
2.551 6,350 1.634
2022
(NRDL) 2,540
2021
2021 3 2022 1 NRDL 2021
4,560
2020 2020 3
4
2021
2,990 8,970
1,260 9,510
2021
2,030 5,880 540
850 2020 7 2021 8
2021 1,720 5.423
2021
6.5
2021 3
2020
2021 7.857 26
5.85 20
2021 4,850 1.649
2,110 7,070
2021 8
2021 4.305 15
3.555 13
2021
3,000 8,350
0 1.095
2021
3,060 1.144 2,350 9,300
5
(SG&A) 2021 SG&A
3.065 9.901 2.082
6.002 SG&A
SG&A
SG&A 2021
SG&A 3,240 1.264
2,600 9,050
2021 5.857 14
0.47 1.17 (ADS) 6.16
15.23 4.727 16
0.40 1.47 (ADS) 5.20 19.13
2021 96.6%
105.3%
2021
8,760 2.180
378% 423%
5,590 1.157
539% 535%
(MCL) (WM)
(MZL) FDA
3,060 1.012
219% 331% (CLL)
2021 3 2022 1
NRDL 440
790
2021
6
2021
5,440
14% 2021
2.551
56%
5
(NRDL)
(NSCLC)
NSCLC (HCC)
(WM)
BRCA(gBRCA)
BTK
(BTK)
45
25
4,000
FDA
(CLL)
(SLL)
2021 6 26 (EHA 2021)
ALPINE 3 (NCT03734016) 2021 12
63 (ASH) SEQUOIA 3 (NCT03336333)
(EMA)
CLL MZL
7
MCL
WM
(WM)
WM
27
WM
MCL MZL WM
40
(NCCN) NCCN
2022.2 del(17p)/TP53 CLL/SLL
2A
CLL/SLL
(NMPA) WM
(sNDA) (CLL)
(SLL) sNDA (BTD)
IgG4 PD-1
Fcγ
35 9,000
NSCLC
3 RATIONALE 305 (NCT03777657)
PD-L1 (G/GEJ)
PD-L1
(OS) (ITT)
OS
8
2021
3 RATIONALE 309(NCT03924986)
(BGB-A1217) Fc TIGIT
25 800
3
2023
6 7
NSCLC 2 AdvanTIG-205
(NCT05014815)
BGB-A445
OX40 BGB-15025
1[HPK1] BGB-10188
PI3Kδ
BGB-23339 1 (NCT05093270) BGB-23339
2(TYK2)
9
(NSCLC)
(HIV) 8 (HHV-8) Castleman (MCD)
MCD(iMCD) EUSA Pharma (UK), Ltd.
β 12
(PR)
(R/R) EUSA Pharma (UK), Ltd.
LBL-007 LAG-3
Zanidatamab HER2 Zymeworks
(NMPA) (CDE)
3 H E R I Z O N - G E A -01 ( N C T05152147)
zanidatamab
HER2 (GEA)
10
688235 34
Margaret Dugan Alessandro Riva
(Sam Su) 4
Mark Lanasa
Kyu-Sung Lee Q
Kevin Mannix
Jurij Petrin
42 17
2022
100 9.3
5.2 6 2023
6
8,000 2022 GMP
64,000
11
2022 R/R CLL/SLL 3 ALPINE
(NCT03734016)
2022 R/R 2 ROSEWOOD
(NCT03332017)
FDA CLL/SLL (BLA)
(PDUFA) FDA
2022 10 22
EMA CLL/MZL
2022
10
2022
(NPC) (ESCC)
(MSI-High)
FDA ESCC
(BLA) (PDUFA) FDA
2022 7 12
2022 NPC NSCLC
2022 HCC 3
(NCT03412773)
12
(Ociperlimab)
2022
2022 1 (NCT04047862)
2022
3 (NCT03519230)
BGB-11417 BCL-2
2022
2022 BGB-A445(OX-40) 1
(NCT04215978)
13
1,000
2021 2020
12 31 12 31
$ 6,624,849 $ 4,658,730
483,113 60,403
587,605 357,686
$ 8,645,949 $ 5,600,757
$ 262,400 $ 231,957
558,055 346,144
407,703 –
390,362 502,848
629,678 518,652
2,402,962 1,731,514
$ 6,242,987 $ 3,869,243
14
ADS ADS 1,000
12 31 3 12 31 12
2021 2020 2021 2020
$ 196,785 $ 100,100 $ 633,987 $ 308,874
17,194 – 542,296 –
213,979 100,100 1,176,283 308,874
48,545 21,078 164,906 70,657
[1] 430,485 355,537 1,459,239 1,294,877
306,501 208,209 990,123 600,176
187 188 750 846
785,718 585,012 2,615,018 1,966,556
(571,739) (484,912) (1,438,735) (1,657,682)
(4,482) (5,186) (15,757) 1,998
(10,583) 8,122 15,904 37,490
(586,804) (481,976) (1,438,588) (1,618,194)
(1,151) (9,327) (25,234) (17,671)
(585,653) (472,649) (1,413,354) (1,600,523)
– 96 – (3,617)
$ (585,653) $ (472,745) $ (1,413,354) $ (1,596,906)
$ (0.47) $ (0.40) $ (1.17) $ (1.47)
1,235,346,414 1,181,005,180 1,206,210,049 1,085,131,783
ADS $ (6.16) $ (5.20) $ (15.23) $ (19.13)
ADS 95,026,647 90,846,552 92,785,388 83,471,676
[1] 2021
3,000 8,350 0 1.095
15
40
2030 20
8,000
http://www.beigene.com.cn
1995 (Private Securities Litigation
Reform Act of 1995)
10-Q
16
(+86 10)5895-8058 (+86 10)6844-5311
ir@beigene.com media@beigene.com
EUSA Pharma (UK), Ltd.
17